Background and aims: Post mortem studies suggest serotonergic dysfunction in Alzheimer's disease (AD), and serotonin 2A (5-HT 2A ) receptors are globally reduced early in the disease. 1 The objective of the study was to investigate serotonin transporters (SERT) as a measure of serotonergic projections 2 in patients with AD and in a mouse model of amyloid plaque deposition. Methods: We included 12 patients (mean age 73.7 ± 7.6 years, 8 males) with Alzheimer's disease (average MMSE of 24, range 19 to 26) and 11 healthy age-matched subjects (mean age 72.5±6.8 years, 6 males). Subjects were investigated with a 90 mins dynamic [ 11 C]DASB-PET to measure SERT and a 40 mins steady-state [ 18 F]altanserin-PET to measure 5-HT 2A receptors. Partial volume correction was applied to correct for atrophy.
There is optimism that b-amyloid (Ab) PET tracers may shift the time-point for accurate diagnosis of Alzheimer's disease (AD) from postmortem to antemortem. BAY 94-9172 is a new Ab-binding 18 F-labeled stilbene derivative currently in clinical development. Within the following the results of a proof of principle study investigating the ability of PET brain scanning with BAY 94-9172 to differentiate subjects with AD from healthy controls (HCs) are presented.
10 subjects with AD (DSM-IV and NINCDS-ADRDA criteria, age = 69±7 yrs, Clinical Dementia Rating (CDR) score = 1 to 2, Mini-Mental State Examination (MMSE) score = 19 ± 7, ApoE4: 6 positive), 10 age-matched healthy controls (HCs, MMSE score Z28, CDR score = 0, ApoE4: 2 positive), as well as 3 patients with fronto-temporal dementia (FTD, Neary consensus criteria as well as MRI and/or [ 18 F]FDG findings compatible with FTD, age = 59 to 78 yrs, MMSE score = 9 to 14, CDR score = 1 to 2, ApoE4: 1 positive) were included. Dynamic brain PET images (ECAT EXACT HR + , B300MBq [ 18 F]BAY 94-9172 i.v., 3D mode, Neuroshield, correction for measured transmission, filtered back-projection) were acquired. The 70 to 90 mins post injection images were analyzed: (1) visually by three blinded experts, (2) by volume of interest (VOI) analysis: VOIs anatomically defined via MRI (1.5 Tesla, 3D T1w volumetric MPRAGE sequence) co-registration, resulting standard uptake value (SUV) ratios using the cerebellar cortex as reference region, (3) via voxelwise, singlecase comparisons with a database created with the PET data from the 10 HCs (SPM2, cluster size > 30 voxel, P < 0.001).
Visual analysis revealed 9 of the 10 AD, but only 1 of the 10 HC brains to be positive for Ab (P < 0.001). In FTD, 2 of the 3 patients were rated positive for Ab. For all subjects, the frequency of ApoE4-positive genotypes was higher in the Ab-positive compared with the Ab-negative PET scans (P = 0.05). When compared to these of the HCs, the SUV ratios in AD subjects were significantly higher in frontal (1.73 ± 0.37 versus 1.35±0.18, P = 0.0098), anterior cingulate (1.72±0.36 versus 1.41±0.15, P = 0.022), posterior Typical [ 18 F]BAY 94-9172 PET images in AD and HC. cingulate (1.79±0.48 versus 1.36±0.13, P = 0.012) and lateral temporal (1.49±0.30 versus 1.24±0.10, P = 0.020) cortices, as well as in caudate heads (1.49±0.30 versus 1.19±0.13, P = 0.010). Voxelwise analyses were in complete agreement with the results of the visual rating. Here, a newly developed Ab load index combining information on extent and severity of pathological tracer uptake was negatively correlated to the MMSE score (r = À0.609, P = 0.004).
These results indicate that [ 18 F]BAY 94-9172 PET scanning has the potential to non-invasively provide accurate and quantitative measures of Ab load during life. As such, this new tracer may facilitate an antemortem diagnosis of AD. Further evaluation of the diagnostic efficacy of [ 18 F]BAY 94-9172 in global, multi-center trials is ongoing. This trial is sponsored and supported by the Bayer-Schering Pharma AG.
38. Identification of human 'non-binders' and measurement of specific binding with [ 11 C](R)-PK 11195: implications for PET imaging of brain inflammation Objective: Ten percent of subjects scanned with [ 11 C]PBR28 show unusual behavior in that the radioligand is unable to bind to the 18 kDa translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor) in brain and in peripheral organs. 1 'Non-binders' have not previously been reported using the older radioligand [ 11 C](R)-PK 11195, possibly because of low specific signal. We measured the displaceable (i.e., specific) binding of [ 11 C](R)-PK 11195 in monkey brain to compare to reported values for [ 11 C]PBR28. We also sought to determine if [ 11 C](R)-PK 11195 could distinguish binders from non-binders in human subjects. Methods: Monkey brain study: Two rhesus monkeys had dedicated brain PET imaging with [ 11 C](R)-PK 11195, both at baseline and after TSPO-blockade using 5 mg/kg of non-radiolabeled PBR28. Total brain activity was measured by calculating total distribution volume (V T ) in each scan using an unconstrained two-tissue compartment model and metabolitecorrected arterial input function. Human whole-body study: Eight healthy human subjects received whole body PET imaging with both [ 11 C](R)-PK 11195 and [ 11 C]PBR28. Four subjects had previously been identified as non-binders with [ 11 C]PBR28. Concentration of radioactivity in organs that express TSPO was measured and corrected for body weight and injected dose. The area under the time-activity curve from 5 to 20 mins was used to measure uptake of radioligand in tissue. Results: Monkey brain study: V T values for [ 11 C](R)-PK 11195 decreased by 52% after pre-treatment with unlabelled PBR28. Specific binding (V S ), calculated as the difference in V T at baseline and blocked conditions, was 57-fold lower than that reported for [ 11 C]PBR28. 2 Human whole-body study: In the [ 11 C]PBR28 scans, non-binders had less uptake than binders in brain, heart, lung, kidney, and spleen (P < 0.001). In the [ 11 C](R)-PK 11195 scans, nonbinders had less uptake (SUV Á min) than binders in the heart [42.6±3.0 (SD) versus 52.8±2.8, P < 0.03] and lung (16.2 ± 2.5 versus 23.1 ± 2.8, P < 0.03). However, [ 11 C](R)-PK 11195 could not distinguish binders and non-binders in the brain, kidney, or spleen. Specific binding of [ 11 C]PBR28, operationally defined as the difference in organ uptake between normal subjects and non-binders, was several-fold higher than that of [ 11 C](R)-PK 11195 in the brain (41-fold), heart (4-fold), lung (4-fold), kidney (15-fold), and spleen (8-fold). Conclusions: In monkey brain, the specific binding of [ 11 C](R)-PK 11195 was 57-fold lower than that of [ 11 C]PBR28. In humans, [ 11 C]PBR28 clearly distinguishes binders from non-binders in each organ studied. We cannot determine if non-binding is a phenomenon shared by [ 11 C](R)-PK 11195, since this radioligand distinguishes non-binders only in the heart and lung, which may be a result of multiple comparisons or of high amounts of nonspecific binding of this ligand. However, [ 11 C]PBR28 has much greater specific binding in monkey and man than Objectives: Desirable properties for amyloid-imaging tracers include good specific retention and rapid clearance of nonspecific binding (given sufficient initial brain entry). The difficulties involved in testing tracers in humans necessitate a robust preclinical protocol for predicting success in humans.
Here we show the utility of measurements of in vitro binding affinity (1/K d ) and nonspecific clearance in animals for predicting relative performance of two amyloid-imaging tracers: PiB and a new [F-18]labeled derivative, 2 0 F-PiB. Methods: Two controls (CN: 75 yrs, 66 yrs, MMSE = 30) and 1 Alzheimer's disease (AD: 57 yrs, MMSE = 28) subject were studied with PET (HR + 10 to 15 mCi) over 90 (PIB) or 120 (2 0 F-PiB) min (no blood sampling). Anesthetized baboons were studied similarly (PiB: n = 8; 2 0 F-PiB: n = 4). Tissue uptake (SUV) and tissue ratios (SUVR) were computed (40 to 90 mins) for frontal cortex (FRC) and cerebellum (CER: nonspecific uptake reference region). Computer simulations were performed to simulate AD time-activity curves for PiB and 2 0 F-PiB. Simulations utilized a legacy 1 PiB input function for an 'average' AD subject and average (n = 9) 2-tissue compartment AD PiB model parameters for FRC (K 1 = 0.254 mL cm À3 min À1 , k 2 = 0.122 min À1 , k 3 = 0.049 min À1 , k 4 = 0.017 min À1 ) and CER (K 1 = 0.283 mL cm À3 min À1 , k 2 = 0.145 min À1 , k 3 = 0.012 min À1 , k 4 = 0.016 min À1 ). Experimental values for in vitro K d of 1.4 nmol/L (PiB) and 5.5 nmol/L (2 0 F-PiB) and the human PiB k 4 values (above) were used to estimate 2 0 F-PiB k 4 values. Results: The 2 0 F-PiB k 4 values for AD FRC and CER were estimated to be 0.067 and 0.063 min À1 , respectively. The simulations predicted an AD PiB FRC SUV value that was 2.0-fold greater than that predicted for 2 0 F-PiB. This suggested that the specific retention of 2 0 F-PiB would be much lower than that of PiB. However, differences in nonspecific clearance could offset this effect when tissue ratios are calculated. This was examined via simulations for CER and in vivo baboon imaging data. The simulations predicted a PiB CER SUV value 1.6-fold higher than that for 2 0 F-PiB. This was consistent with PET data acquired in amyloid-free baboons for which the experimentally determined PiB CER SUV was 1.6fold higher than that measured for 2 0 F-PiB. These results suggest that the PiB FRC SUVR would be B1.3-fold greater that of 2 0 F-PiB (i.e., 2.0/1.6). The findings in humans were very consistent with these predictions. PET studies in the AD patient resulted in a PiB FRC SUV value that was 2.3-fold higher than that measured for 2 0 F-PiB, while the PiB CER SUV was 1.6-fold higher (and similar across all 3 subjects: 1.7 ± 0.2). PET studies in the AD subject also yielded a PiB FRC SUVR value of 3.1, a value that was 1.4fold higher than the 2 0 F-PiB FRC SUVR value of 2.2. Conclusions: This comparison of experimentallydriven K d simulations with animal studies of nonspecific clearance was robust relative to human in vivo PET data results and shows the value of experimentally-determined affinity and clearance in predicting in vivo performance of amyloid-imaging tracers in humans.
